| Original language | English (US) |
|---|---|
| Pages (from-to) | 970-971 |
| Number of pages | 2 |
| Journal | The Lancet Neurology |
| Volume | 19 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2020 |
Funding
SM reports consultation fees for advisory board meetings from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, unrelated to this Correspondence. JTG reports personal fees for advisory boards from Immunovant, Alexion Pharmaceuticals, Cabaletta Bio, Regeneron Pharmaceuticals, argenx, and Momenta Pharmaceuticals and grants from Ra Pharmaceuticals, unrelated to this Correspondence. SJ has served as an international advisory board member for Alexion Pharmaceuticals, Alnylam Pharmaceuticals, and Regeneron Pharmaceuticals; is currently an expert panel member of myasthenia gravis consortium for argenx, has worked as chief or principal investigator for myasthenia trials by Alexion Pharmaceuticals, argenx, Momenta Pharmaceuticals, and UCB and has received speaker fees from Terumo Blood and Cell Technologies and Eisai, unrelated to this Correspondence. ACG has received research support from the Myasthenia Gravis Foundation of America and Myasthenia Gravis Rare Disease Network; clinical trial funding and consultant fees or honoraria from Momenta Pharmaceuticals, Ra Pharmaceuticals, and Alexion Pharmaceuticals; and publishing royalties from Oakstone Publishing, unrelated to this Correspondence. JFHJ has received research support from Alexion Pharmaceuticals, argenx, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, Ra Pharmaceuticals; honoraria from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, Regeneron Pharmaceuticals, and Viela Bio; and non-financial support from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, and Toleranzia, unrelated to this Correspondence. GC reports personal fees from MedDay Pharmaceuticals during the conduct of the study; personal fees for data safety monitoring boards from AstraZeneca, Avexis, BioLineRx, BrainStorm Cell Therapeutics, Bristol Myers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Mapi Pharmaceuticals, Merck, Merck/Pfizer, Opko Biologics, Neurim, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, Viela Bio, Vivus, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, unrelated to this Correspondence; personal fees for consulting or advisory board from Biogen, Click Therapeutics, Sanofi Genzyme, Genentech, GW Pharmaceuticals, Klein-Buendel, MedImmune, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion Pharmaceuticals/CereXis, Roche, Somahlution, and TG Therapeutics; and personal fees from Pythagoras, unrelated to this Correspondence. HW reports grants and personal fees from Abbvie, Biogen, Merck Serono, Sanofi Genzyme; personal fees from Evgen, MedDay Pharmaceuticals, Novartis, Roche Pharmaceuticals, Immunic, Alexion Pharmaceuticals, Actelion, F Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Lundbeck, Teva Pharmaceuticals, WebMD Global; grants from Federal Ministry for Education and Research, Deutsche Forschungsgesellschaft, Else Kröner Fresenius Foundation, EU, Fresenius Foundation, Hertie Foundation, North Rhine-Westphalia Ministry of Education and Research, Interdisciplinary Center for Clinical Studies Muenster, Rasmussen's Encephalitis Children's Foundation, Progressive Multifocal Leukoencephalopathy Consortium, Swiss Multiple Sclerosis Society, and GSK, unrelated to this Correspondence. MBM receives grant funding from the National Institutes of Health and the Agency for Healthcare Research and Quality, unrelated to this Correspondence. HM reports personal fees from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, and UCB; and grants from Japan Blood Products Organization and Ministry of Health, Labour and Welfare, Japan, unrelated to this Correspondence. KU has served as a paid consultant for argenx, Ra Pharmaceuticals, UCB, and Viela Bio and has received speaker honoraria from the Japan Blood Products Organization and Alexion Pharmaceuticals, unrelated to this Correspondence. RJN has received research support from Alexion Pharmaceuticals, argenx, Genentech, Grifols, Immunovant, Momenta Pharmaceuticals, the Myasthenia Gravis Foundation of America, the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Institute of Allergy and Infectious Diseases), and Ra Pharmaceuticals; and consultancy fees from Alexion Pharmaceuticals, argenx, CSL Behring, Grifols, Immunovant, Momenta Pharmaceuticals, Ra Pharmaceuticals, Roivant Sciences, and Viela Bio, unrelated to this Correspondence. RM has received funding for travel or meeting attendance from Alexion Pharmaceuticals, argenx, Biomarin Pharmaceuticals, Novartis, Catalyst Pharmaceuticals, Merck Serono, and UCB and for advisory board participation from Alexion Pharmaceuticals, argenx, UCB, and Regeneron Pharmaceuticals. All other authors declare no competing interests. SM, JTG, and RJN contributed equally.
ASJC Scopus subject areas
- Clinical Neurology